<DOC>
	<DOCNO>NCT00274651</DOCNO>
	<brief_summary>Open-label , non-randomized trial ass effectiveness PXD101 patient recurrent refractory cutaneous peripheral type T-cell lymphoma . PXD101 new , potent histone deacetylase ( HDAC ) inhibitor . Patients treat belinostat ( PXD101 ) 1000 mg/m2 day 1-5 21 day cycle .</brief_summary>
	<brief_title>A Phase II Clinical Trial PXD101 Patients With Recurrent Refractory Cutaneous Peripheral T-Cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>Male female age &gt; = 18 year . Histologically confirm diagnosis cutaneous Tcell lymphoma ( CTCL ) peripheral Tcell lymphoma ( PTCL ) Tcell nonHodgkin 's lymphoma ( NHL ) . Must fail least one line prior systemic therapy . No limitation number prior therapy . CTCL patient refractory intolerant oral Targretin also eligible . The presence measurable disease ( define &gt; = 1 cm radiographic imaging ) PTCL stage 1B great disease CTCL assessable severityweighted assessment tool ( SWAT ) . Adequate bone marrow hepatic function include follow : Absolute neutrophil count &gt; = 1,000 cells/mm3 , platelet &gt; = 40,000/mm3 Total bilirubin &lt; = 1.5 x upper normal limit &lt; = 3 x upper normal limit hepatic involvement AST ( SGOT ) ( aspartate aminotransferase ) , ALT ( SGPT ) ( alanine aminotransferase ) &lt; = 2.5 x upper normal limit ( &lt; = 5 x upper normal limit hepatic involvement ) Hemoglobin &gt; = 9.0 g/dL . Serum potassium within normal range . Karnofsky performance status &gt; = 70 % . Estimated life expectancy &gt; 3 month . Signed informed consent approve Institutional Review Board ( IRB ) . Anticancer therapy within 4 week first PXD101 administration exclude unless toxicity prior anticancer therapy resolve returned baseline cancer disease status warrant . Any use investigational drug within 4 week prior study registration . Major surgery within 4 week study drug administration . Prior allogeneic bone marrow transplant . A diagnosis adult Tcell lymphoma/leukemia ( ATLL ) precursor Tlymphoblastic lymphoma . Coexisting active infection coexist medical condition likely interfere trial procedure . However , patient progress CTCL whose open skin lesion frequently infect may exclude trial discretion Investigators . Clinically significant cardiovascular disease include unstable angina pectoris , uncontrolled hypertension , congestive heart failure relate primary cardiac disease , condition require antiarrhythmic therapy , history sustain ventricular tachycardia , history ventricular fibrillation Torsade de Pointes , bradycardia ( HR &lt; 50bpm ) without pacemaker , bifascicular block right bundle branch block leave anterior block , ischemic severe valvular heart disease , myocardial infarction within 6 month leave ventricular ejection fraction &lt; 40 % ( echocardiogram [ ECHO ] multigated acquisition scan [ MUGA ] ) within 3 month study enrolment . A marked baseline prolongation QT/QTc ( ( correct ) QT ) interval , e.g. , repeat demonstration QTc interval &gt; 450 millisecond ( msec ) . Long QT Syndrome ; require use concomitant medication belinostat infusion day may cause Torsade de Pointes . Renal insufficiency define calculated creatinine clearance &lt; 45 mL/min/1.73 m2 . A history allergic reaction attribute compound similar chemical biological composition PXD101 Larginine . Clinically significant central nervous system disorder alter mental status psychiatric disorder preclude understanding informed consent process and/or completion necessary study . Patients require treatment malignant diseases less 5 year posttreatment completion invasive malignant disease ( exclude nonmelanotic skin cancer cervical cancer insitu ) . Patients history melanoma exclude . Pregnant breastfeed woman , woman childbearing age potential , willing use effective contraception . Male patient and/or fertile female partner willing use contraceptives trial . Known infection HIV , human Tcell leukemia virus type1 ( HTLV1 ) , hepatitis B hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>CTCL</keyword>
	<keyword>PTCL</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Cutaneous T-Cell Lymphomas ( CTCL )</keyword>
	<keyword>Peripheral T-Cell Lymphomas ( PTCL )</keyword>
	<keyword>Other Types Non-Hodgkin 's Lymphoma</keyword>
	<keyword>belinostat</keyword>
</DOC>